Related references
Note: Only part of the references are listed.Lifestyle factors and risk of myeloproliferative neoplasms in the NIH-AARP diet and health study
Nikolai A. Podoltsev et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map
Rory M. Shallis et al.
BLOOD REVIEWS (2020)
Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden
Theodoros Karantanos et al.
BLOOD ADVANCES (2020)
Diet and Risk of Myeloproliferative Neoplasms in Older Individuals from the NIH-AARP Cohort
Nikolai A. Podoltsev et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Sabrina Cordua et al.
BLOOD (2019)
Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014
Peter D. Baade et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing
Karl Kashofer et al.
LEUKEMIA & LYMPHOMA (2018)
Familial risks of acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms
Amit Sud et al.
BLOOD (2018)
GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis
Ayalew Tefferi et al.
LEUKEMIA (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Smoking is associated with increased risk of myeloproliferative neoplasms: A general population-based cohort study
Kasper M. Pedersen et al.
CANCER MEDICINE (2018)
Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013
Ja Min Byun et al.
ANNALS OF HEMATOLOGY (2017)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway
Christina Roaldsnes et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2017)
Adapting to obesity with adipose tissue inflammation
Shannon M. Reilly et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
S. Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Obesity and related risk of myeloproliferative neoplasms among israeli adolescents
Adi Leiba et al.
OBESITY (2017)
Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population
Yi-Hao Chiang et al.
ONCOTARGET (2017)
Gender and survival in essential thrombocythemia: A two-center study of 1,494 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms
Elisa Rumi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Smoking and philadelphia-negative chronic myeloproliferative neoplasms
Anders Lindholm Sorensen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms
David A. Hinds et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12
Samer A. Srour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms
Natasha Szuber et al.
JOURNAL OF CLINICAL PATHOLOGY (2016)
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Brazilian patients
L. C. Macedo et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms
William Tapper et al.
NATURE COMMUNICATIONS (2015)
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms
Roland Jaeger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
How common are myeloproliferative neoplasms? A systematic review and meta-analysis
Glen J. Titmarsh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
A novel germline JAK2 mutation in familial myeloproliferative neoplasms
Elisa Rumi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis
S. Leah Etheridge et al.
BLOOD (2014)
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Ayalew Tefferi et al.
BLOOD (2014)
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union
Odile Moulard et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2014)
JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate
Camilla Nielsen et al.
HAEMATOLOGICA (2014)
Anthropometric, medical history and lifestyle risk factors for myeloproliferative neoplasms in The Iowa Women's Health Study cohort
Alexis D. Leal et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The germline sequence variant rs2736100_C in TERT associates with myeloproliferative neoplasms Open
A. Oddsson et al.
LEUKEMIA (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Survival Patterns in United States (US) Medicare Enrollees with Non-CML Myeloproliferative Neoplasms (MPN)
Gregory L. Price et al.
PLOS ONE (2014)
Impact of isolated germline JAK2V617I mutation on human hematopoiesis
Adam J. Mead et al.
BLOOD (2013)
Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population
Camilla Nielsen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Risk of adult acute and chronic myeloid leukemia with cigarette smoking and cessation
Jessica R. B. Musselman et al.
CANCER EPIDEMIOLOGY (2013)
Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study
Marc Maynadie et al.
HAEMATOLOGICA (2013)
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients
Mayumi Tanaka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
A. Tefferi et al.
LEUKEMIA (2013)
JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
J. Wang et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Unique features of primary myelofibrosis in Chinese
Zefeng Xu et al.
BLOOD (2012)
Incidence, survival and prevalence of myeloid malignancies in Europe
O. Visser et al.
EUROPEAN JOURNAL OF CANCER (2012)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study
Malin Hultcrantz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Influence of JAK2 46/1 haplotype in the natural evolution of JAK2V617F allele burden in patients with myeloproliferative neoplasms
Alberto Alvarez-Larran et al.
LEUKEMIA RESEARCH (2012)
One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
Ayalew Tefferi et al.
MAYO CLINIC PROCEEDINGS (2012)
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations
Francesco Passamonti et al.
BLOOD (2011)
Chromosome-wide aneuploidy study (CWAS) in workers exposed to an established leukemogen, benzene
Luoping Zhang et al.
CARCINOGENESIS (2011)
The JAK2 V617F somatic mutation, mortality and cancer risk in the general population
Camilla Nielsen et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Autoimmunity and the risk of myeloproliferative neoplasms
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Jakking up Tumor Registry reporting of the myeloproliferative neoplasms
H. Andrew Selinger et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
Risks of myeloid malignancies in patients with autoimmune conditions
L. A. Anderson et al.
BRITISH JOURNAL OF CANCER (2009)
A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms
Outi Kilpivaara et al.
NATURE GENETICS (2009)
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms
Amy V. Jones et al.
NATURE GENETICS (2009)
Prevalence of polycythemia vera and essential thrombocythemia
Xiaomei Ma et al.
AMERICAN JOURNAL OF HEMATOLOGY (2008)
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs
Dana E. Rollison et al.
BLOOD (2008)
Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation
Elisa Rumi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis
Linda M. Scott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia
P Johansson
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors
AP Wolanskyj et al.
MAYO CLINIC PROCEEDINGS (2006)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
A long-term retrospective study of young women with essential thrombocythemia
A Tefferi et al.
MAYO CLINIC PROCEEDINGS (2001)
Share Paper
